Today: 7 February 2026
Subscribe
Browse Category

Pharmaceuticals News 20 December 2025 - 21 December 2025

Recursion Pharmaceuticals RXRX Stock News and Forecasts on December 21 2025

Recursion Pharmaceuticals RXRX Stock News and Forecasts on December 21 2025

Recursion Pharmaceuticals, Inc. stock (NASDAQ: RXRX) heads into the week of December 21, 2025 with investors focused on one thing above all: whether newly released clinical data can turn Recursion’s long-running “AI drug discovery” promise into a credible, repeatable pipeline story that ultimately becomes commercial revenue. The near-term backdrop is noisy. RXRX has been highly volatile for years, and even now the share price sits far below its prior highs, a reality that shapes how every catalyst is interpreted. The Motley Fool Below is a roundup of the key RXRX stock news, fresh filings, analyst forecasts, and the most cited
21 December 2025
···
Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Forecasts, Dividend Outlook, and Pipeline Catalysts (Updated Dec. 21, 2025)

Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Forecasts, Dividend Outlook, and Pipeline Catalysts (Updated Dec. 21, 2025)

Pfizer Inc. (NYSE: PFE) is heading into 2026 with a familiar mix of strengths and stress fractures: a fortress-scale commercial footprint and one of Big Pharma’s deepest development machines—paired with fading COVID-era revenue, looming loss-of-exclusivity headwinds, and heightened political pressure on U.S. drug pricing. As of the most recent close (Friday, Dec. 19), Pfizer stock finished around $25.19, leaving shares squarely in the “mid‑$20s” range where they’ve been pinned for much of the post-pandemic reset. MarketBeat+1 What changed in December—and why investors are still arguing about Pfizer stock—comes down to three big storylines: Below is a comprehensive, up-to-date roundup of
21 December 2025
··
AbbVie Stock (ABBV) Outlook: Drug‑Pricing Deal Headlines, Fresh Analyst Targets, and the 2026 Catalysts Investors Are Watching

AbbVie Stock (ABBV) Outlook: Drug‑Pricing Deal Headlines, Fresh Analyst Targets, and the 2026 Catalysts Investors Are Watching

December 21, 2025 — AbbVie Inc. (NYSE: ABBV) heads into the final stretch of 2025 near multi‑month highs, but the weekend news cycle (starting December 20, 2025) has put a familiar theme back in the spotlight: U.S. drug pricing policy. At the same time, Wall Street’s newest notes show a market still split between strong fundamentals (Skyrizi/Rinvoq momentum and a dividend raise) and policy/pipeline debates that could shape sentiment into 2026. ABBV last traded around $226.82 after Friday’s session, up about 1.8% on the day, and sitting within striking distance of its 52‑week high. MarketWatch Where AbbVie stock stands as
21 December 2025
··
Amgen Stock (AMGN) News Today: TrumpRx Drug-Price Deal, FDA Approvals, Dividend Update, and 2026 Analyst Forecasts

Amgen Stock (AMGN) News Today: TrumpRx Drug-Price Deal, FDA Approvals, Dividend Update, and 2026 Analyst Forecasts

December 20, 2025 — Amgen Inc. (NASDAQ: AMGN) is closing out the year with a rare combination of near-term policy headlines and company-specific catalysts that matter to investors: a new U.S. drug-pricing deal tied to the TrumpRx rollout, fresh FDA approvals that expand the growth runway, reaffirmed shareholder returns via dividends, and a split—but active—Wall Street outlook heading into 2026. AMGN last traded around $327.38, reflecting the most recent available market print (U.S. markets are closed today). Below is a detailed, publication-ready breakdown of today’s key Amgen stock news, along with forecasts and analyst analysis relevant as of 20.12.2025. What’s
20 December 2025
·
Johnson & Johnson Stock JNJ: Talc Verdict, Drug Pricing Pressure, and the 2026 Forecast as of Dec. 20, 2025

Johnson & Johnson Stock JNJ: Talc Verdict, Drug Pricing Pressure, and the 2026 Forecast as of Dec. 20, 2025

Dec. 20, 2025 — Johnson & Johnson (NYSE: JNJ) is closing out the week with investors weighing a fresh talc-related jury verdict, a fast-moving U.S. drug-pricing policy push that could soon reach J&J, and a stream of late-2025 catalysts spanning FDA-related updates, M&A, and a major MedTech restructuring plan. JNJ shares last traded around $206.37, down about 0.9% from the prior close, after touching higher levels earlier in the week. The bigger picture: J&J has delivered a strong 2025 run by large-cap healthcare standards, with total return measures showing roughly high‑40% year-to-date performance by mid-to-late December. Finance Charts Johnson &
20 December 2025
·
Eli Lilly (LLY) Stock Outlook on Dec. 20, 2025: Orforglipron Pill Data, Price Cuts, and 2026 Forecasts Put the $1 Trillion Drugmaker Back in Focus

Eli Lilly (LLY) Stock Outlook on Dec. 20, 2025: Orforglipron Pill Data, Price Cuts, and 2026 Forecasts Put the $1 Trillion Drugmaker Back in Focus

Dec. 20, 2025 — Eli Lilly and Company (NYSE: LLY) is closing out 2025 with momentum—and with fresh headlines that underscore why Eli Lilly stock has become one of the market’s most closely watched healthcare names. Shares last closed at $1,071.44 (Dec. 19) after trading between $1,059.01 and $1,075.38, keeping the stock within reach of its recent highs. Stock Analysis The bigger story isn’t just the price. Lilly entered the rarefied “$1 trillion market value” club this year—an inflection point for a pharmaceutical company—and it’s doing so on the back of a rapidly expanding obesity and cardiometabolic franchise, a pipeline
20 December 2025
···
Recursion Pharmaceuticals Stock (RXRX) News and Forecasts for Dec. 20, 2025: TUPELO Trial Data, JPMorgan Upgrade, and What Comes Next

Recursion Pharmaceuticals Stock (RXRX) News and Forecasts for Dec. 20, 2025: TUPELO Trial Data, JPMorgan Upgrade, and What Comes Next

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) heads into the weekend of December 20, 2025 with investors still digesting a fast-moving sequence of catalysts: fresh clinical data for its lead program REC-4881, a notable JPMorgan upgrade, and a burst of unusually heavy trading volume that has kept the stock in the spotlight. Because U.S. markets are closed on Saturday, the most recent trading reference is Friday’s close (Dec. 19, 2025). RXRX last traded around $4.26 after a volatile week that included a one-day surge and a quick pullback. StockAnalysis RXRX stock price action this week: the “upgrade pop” meets reality checks RXRX’s
20 December 2025
···
Pfizer Stock (PFE) News Today: 2026 Guidance, TrumpRx Drug-Pricing Deals, Dividend, and Analyst Forecasts (Dec. 20, 2025)

Pfizer Stock (PFE) News Today: 2026 Guidance, TrumpRx Drug-Pricing Deals, Dividend, and Analyst Forecasts (Dec. 20, 2025)

Pfizer Inc. stock (NYSE: PFE) is ending the week in a familiar place: the mid-$20s. But the story behind that “quiet” price is anything but quiet. Investors are weighing Pfizer’s newly issued 2026 outlook, an evolving U.S. drug-pricing landscape tied to the TrumpRx / most-favored-nation (MFN) framework, and a pipeline-and-deal strategy meant to carry the company through a multi-year patent cliff and the long fade of COVID-era revenue. Reuters+1 Pfizer stock price snapshot: where PFE stands on Dec. 20, 2025 With U.S. markets closed for the weekend, the latest available quote has Pfizer shares around $25.19, after a volatile stretch
20 December 2025
···
Vertex Pharmaceuticals (VRTX) Stock After Hours on Dec. 19, 2025: Today’s News, Analyst Forecasts, and What to Know Before Monday’s Market Open

Vertex Pharmaceuticals (VRTX) Stock After Hours on Dec. 19, 2025: Today’s News, Analyst Forecasts, and What to Know Before Monday’s Market Open

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) finished Friday, December 19, 2025, on a strong note and then stayed relatively steady in after-hours trading—setting up a familiar “what happens next?” question for investors heading into the final full week before year-end. Below is a detailed rundown of what moved VRTX today, what the after-hours tape is saying, what analysts are forecasting right now, and the key catalysts to watch before the next U.S. market open (Monday, December 22, 2025). VRTX after the bell: where the stock closed and how it traded after hours VRTX rose 1.97% in the regular session to close
20 December 2025
··
Gilead Sciences Stock (GILD) After Hours on Dec. 19, 2025: TrumpRx Pricing Deal, UK Lenacapavir Approval, and What to Watch Before the Next Market Open

Gilead Sciences Stock (GILD) After Hours on Dec. 19, 2025: TrumpRx Pricing Deal, UK Lenacapavir Approval, and What to Watch Before the Next Market Open

Gilead Sciences, Inc. (NASDAQ: GILD) ended Friday, December 19, 2025, with a sharp, high-volume move that kept traders focused into the after-hours session. The headline drivers were a new U.S. government pricing agreement tied to TrumpRx.gov and tariff relief, plus a fresh U.K. regulatory approval for lenacapavir—two catalysts that hit the tape on the same day and helped explain why Gilead was among the stronger large-cap pharma names into the close. Gilead stock price recap after the bell (Dec. 19 close + after-hours) Gilead’s regular session finished firmly higher, and the after-hours tape stayed constructive but calm. One notable detail:
20 December 2025
··
Merck (MRK) Stock After Hours on Dec. 19, 2025: Trump Drug-Pricing Deal, FDA Fast-Track Vouchers, and What to Watch Before Markets Reopen

Merck (MRK) Stock After Hours on Dec. 19, 2025: Trump Drug-Pricing Deal, FDA Fast-Track Vouchers, and What to Watch Before Markets Reopen

Merck & Co., Inc. (NYSE: MRK) finished Friday’s regular session (Dec. 19, 2025) modestly higher, then eased slightly in after-hours trading as investors digested a headline-heavy day featuring U.S. drug-pricing policy moves and FDA acceleration for two major Merck pipeline assets. Below is what happened after the bell, why it matters, and the key items to track before the next U.S. market open (Monday, Dec. 22, 2025). MRK stock price after the bell: the key numbers Merck shares closed at $101.09, up $0.40 (+0.40%) on Friday. Zacks+1 In after-hours trading, MRK was slightly lower, trading around $100.9–$101.0 in early evening
20 December 2025
··
Eli Lilly Stock After Hours (Dec. 19, 2025): LLY Closes Higher on Obesity-Pill Momentum—What to Watch Before the Next Market Open

Eli Lilly Stock After Hours (Dec. 19, 2025): LLY Closes Higher on Obesity-Pill Momentum—What to Watch Before the Next Market Open

Eli Lilly and Company (NYSE: LLY) ended Friday, December 19, 2025, with a solid gain, then barely budged in after-hours trading—an important clue about how investors are digesting the latest wave of obesity-drug headlines heading into next week. One key calendar note up front: U.S. stock markets do not open on Saturdays. With December 19 falling on a Friday, the next regular stock-market open is Monday, December 22, 2025 (barring any exchange-specific changes). LLY stock price after the bell: how Eli Lilly traded after hours on Dec. 19 That “strong close / quiet after-hours” pattern typically signals that Friday’s move
20 December 2025
···
1 … 33 34 35 36 37 … 56

Stock Market Today

Stellantis stock slides 24% after €22 billion EV reset kills 2026 dividend — what to watch next

Stellantis stock slides 24% after €22 billion EV reset kills 2026 dividend — what to watch next

7 February 2026
Stellantis shares plunged 23.7% to $7.28 Friday after the company disclosed about €22.2 billion in charges tied to a reset of its electric-vehicle strategy and said it will skip its 2026 dividend. The automaker flagged a preliminary net loss of €19–21 billion for the second half of 2025. Shares rose 1.6% in late after-hours trading. Investors await Feb. 26 results and a May 21 Investor Day.
Intel stock jumps on China server CPU delays as traders map the week ahead

Intel stock jumps on China server CPU delays as traders map the week ahead

7 February 2026
Intel shares rose 4.87% to $50.59 Friday, trailing gains by Nvidia and Broadcom as chip stocks rallied. Sources said Intel and AMD warned Chinese customers of longer waits and higher prices for some server CPUs, with Intel lead times reaching six months. Intel said China accounts for over 20% of its revenue. Investors await key U.S. jobs and inflation data next week.
IRS tax refund delays? Watchdog flags staffing crunch as 2026 filing season ramps up

IRS tax refund delays? Watchdog flags staffing crunch as 2026 filing season ramps up

7 February 2026
IRS staffing has dropped to 2021 levels as the 2026 tax filing season begins, according to a Treasury watchdog. The agency faces a backlog of about 2 million returns, 129% above pre-pandemic levels. Most e-filers using direct deposit still get refunds within 21 days, but paper filings and amended returns could see delays. The IRS lowered its call-answer target to 70% for this season.
Plug Power stock jumps 12% after vote setback, with Feb 17 share decision in focus

Plug Power stock jumps 12% after vote setback, with Feb 17 share decision in focus

7 February 2026
Plug Power shares rose 11.6% Friday to $2.08 after a sharp drop the previous day, as attention shifted to a Feb. 17 shareholder vote on expanding authorized shares. The company failed to secure enough votes earlier this week and is urging overseas holders to participate. CEO Andy Marsh cited difficulties for European investors in casting ballots. A reverse stock split remains possible if the proposal fails.
Go toTop